合成生物学周报：上海百亿产业基金支持合成生物发展，常德四大合成生物项目正式签约

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Biological Economy Development," indicating a trillion-yuan market potential in the biological economy [4]. Summary by Sections 1. Synthetic Biology Market Dynamics - The synthetic biology sector has shown a positive performance, with an increase of 0.82% in the Huazhong Synthetic Biology Index during the week of January 6-10, 2025, ranking 7th among various sectors [20][22]. - The top five performing companies in the synthetic biology sector during this period were Jinbo Bio (+5%), Shengquan Group (+5%), Aibo Medical (+3%), Juzhi Bio (+3%), and Tebao Bio (+3%) [22]. 1.2 Company Business Developments - Huisi Le Health Technology and Aibio have signed a strategic cooperation agreement to promote the integration of synthetic biology and AI technology, focusing on the development of peptide raw materials [28]. - Henan Huiyang's project for the annual production of 1,000 tons of high molecular weight polylactic acid has commenced, with a total investment of 500 million yuan, aiming for an annual revenue of 600-800 million yuan [29]. - Zhejiang Tianfu Hongyun's project for the annual production of 400,000 tons of biodiesel has been accepted for environmental assessment, with an investment of 800 million yuan [30]. 1.3 Industry Financing Tracking - The financing in the synthetic biology sector has accelerated, with nearly a hundred companies completing new financing rounds at the beginning of 2024. For instance, Libang Pharmaceutical completed a C round financing of 550 million yuan to support its kidney disease drug development [33]. - Inari, a company based on synthetic biology technology, announced a financing of 144 million USD, bringing its total equity financing to over 720 million USD [33].